Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19
David Schub, … , Martina Sester, Tina Schmidt
David Schub, … , Martina Sester, Tina Schmidt
Published September 16, 2020
Citation Information: JCI Insight. 2020;5(20):e142167. https://doi.org/10.1172/jci.insight.142167.
View: Text | PDF
Clinical Research and Public Health COVID-19

High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19

  • Text
  • PDF
Abstract

BACKGROUND Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differ in the severity of disease. We hypothesized that characteristics of SARS-CoV-2–specific immunity correlate with disease severity.METHODS In this study, SARS-CoV-2–specific T cells and antibodies were characterized in uninfected controls and patients with different coronavirus disease 2019 (COVID-19) disease severity. SARS-CoV-2–specific T cells were flow cytometrically quantified after stimulation with SARS-CoV-2 peptide pools and analyzed for expression of cytokines (IFN-γ, IL-2, and TNF-α) and markers for activation, proliferation, and functional anergy. SARS-CoV-2–specific IgG and IgA antibodies were quantified using ELISA. Moreover, global characteristics of lymphocyte subpopulations were compared between patient groups and uninfected controls.RESULTS Despite severe lymphopenia affecting all major lymphocyte subpopulations, patients with severe disease mounted significantly higher levels of SARS-CoV-2–specific T cells as compared with convalescent individuals. SARS-CoV-2–specific CD4+ T cells dominated over CD8+ T cells and closely correlated with the number of plasmablasts and SARS-CoV-2–specific IgA and IgG levels. Unlike in convalescent patients, SARS-CoV-2–specific T cells in patients with severe disease showed marked alterations in phenotypical and functional properties, which also extended to CD4+ and CD8+ T cells in general.CONCLUSION Given the strong induction of specific immunity to control viral replication in patients with severe disease, the functionally altered characteristics may result from the need for contraction of specific and general immunity to counteract excessive immunopathology in the lung.FUNDING The study was supported by institutional funds to MS and in part by grants of Saarland University, the State of Saarland, and the Rolf M. Schwiete Stiftung.

Authors

David Schub, Verena Klemis, Sophie Schneitler, Janine Mihm, Philipp M. Lepper, Heinrike Wilkens, Robert Bals, Hermann Eichler, Barbara C. Gärtner, Sören L. Becker, Urban Sester, Martina Sester, Tina Schmidt

×

Figure 2

Increased percentages of SARS-CoV-2–specific T cells in patients with severe COVID-19.

Options: View larger image (or click on image) Download as PowerPoint
Increased percentages of SARS-CoV-2–specific T cells in patients with se...
Whole-blood samples were stimulated with overlapping peptide pools spanning the SARS-CoV-2 spike protein (spike N, N-terminal; spike C, C-terminal), the NCAP protein, the membrane protein VME1, and the envelope small membrane protein VEMP. Stimulations with DMSO and SEB served as negative controls and polyclonal stimulus, respectively. (A) Contour plots illustrating specific immunity from a 56-year-old hospitalized patient are shown. Numbers indicate percentage of reactive (CD69+IFN-γ+) cells within total CD4+ and CD8+ T cells. (B) Percentages of CD4+ and CD8+ T cells specific for the different SARS-CoV-2 antigens were compared between SARS-CoV-2–negative individuals (negative, n = 10), patients with severe COVID-19 (ICU, n = 14), and convalescent patients (n = 36). (C) Total percentages of SARS-CoV-2–specific (CD69+IFN-γ+) T cells, determined by the sum of frequencies toward the individual peptide pools for each individual, and SEB-reactive T cell frequencies are compared between the 3 groups. Bars represent medians with IQRs. Differences between the groups were calculated using Kruskal-Wallis test and Dunn’s posttest. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts